Complete remission of lupus nephritis with rituximab and steroids for induction and rituximab alone for maintenance therapy

Détails

ID Serval
serval:BIB_CD425C453CD6
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Complete remission of lupus nephritis with rituximab and steroids for induction and rituximab alone for maintenance therapy
Périodique
Am J Kidney Dis
Auteur⸱e⸱s
Camous L., Melander C., Vallet M., Squalli T., Knebelmann B., Noel L. H., Fakhouri F.
ISSN
1523-6838 (Electronic)
ISSN-L
0272-6386
Statut éditorial
Publié
Date de publication
08/2008
Volume
52
Numéro
2
Pages
346-52
Langue
anglais
Notes
Camous, Laurent
Melander, Catherine
Vallet, Marion
Squalli, Tarek
Knebelmann, Bertrand
Noel, Laure-Helene
Fakhouri, Fadi
eng
Case Reports
Am J Kidney Dis. 2008 Aug;52(2):346-52. doi: 10.1053/j.ajkd.2008.03.036. Epub 2008 Jun 24.
Résumé
Lupus nephritis (LN) is a severe and frequent complication of systemic lupus erythematosus. For decades, cyclophosphamide-based regimens have been the gold standard in treating patients with LN. However, cyclophosphamide use is associated with increased morbidity and mortality, and thus alternative treatments are needed. We report 3 cases of severe class IV LN successfully treated with rituximab as an induction, as well as a long-term maintenance, treatment. Complete remission of LN, documented by means of a control kidney biopsy, occurred in all patients and was maintained during follow-up using rituximab as sole maintenance treatment. No severe infectious complications were observed during treatment with rituximab. Our data suggest that rituximab may prove to be an optimal maintenance treatment in patients with severe LN.
Mots-clé
Adult, Antibodies, Monoclonal/administration & dosage/*therapeutic use, Antibodies, Monoclonal, Murine-Derived, Biopsy, Cell Proliferation, Dose-Response Relationship, Drug, Drug Therapy, Combination, Follow-Up Studies, Glucocorticoids/administration & dosage/*therapeutic use, Humans, Immunologic Factors/administration & dosage/*therapeutic use, Infusions, Intravenous, Kidney/pathology, Lupus Nephritis/*drug therapy/pathology, Microscopy, Fluorescence, Remission Induction, Rituximab, Severity of Illness Index, Time Factors
Pubmed
Création de la notice
01/03/2022 10:18
Dernière modification de la notice
02/03/2022 6:36
Données d'usage